Phase I/II trial of bevacizumab plus erlotinib for patients with recurrent non-small cell lung cancer: Correlation of treatment response with mutations of the EGFR tyrosine kinase gene
Tsao A, Herbst R, Sandler A, Seshagiri S, Wistuba I, Henderson T, Ramies D, Goddard A, Johnson D, Eberhard D. Phase I/II trial of bevacizumab plus erlotinib for patients with recurrent non-small cell lung cancer: Correlation of treatment response with mutations of the EGFR tyrosine kinase gene. Journal Of Clinical Oncology 2005, 23: 7092-7092. DOI: 10.1200/jco.2005.23.16_suppl.7092.Peer-Reviewed Original Research